Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 12.89% year-over-year to $7.3 billion in Q1 2026; TTM through Mar 2026 was $7.3 billion, a 12.89% increase from a year earlier, with the FY2025 full-year figure at $7.3 billion, up 6.56% from the prior year.
• Total Non-Current Liabilities held at $7.3 billion in Q1 2026 per REGN's latest filing, from $7.3 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $7.3 billion in Q3 2025 and bottomed at $5.6 billion in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $6.5 billion (2024), against an average of $6.5 billion.
• Across the five-year window, Total Non-Current Liabilities increased 27.92% in 2023 and dropped 8.91% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $5.9 billion in 2022, then increased by 5.76% to $6.3 billion in 2023, then climbed by 9.3% to $6.8 billion in 2024, then gained by 6.56% to $7.3 billion in 2025, then grew by 0.49% to $7.3 billion in 2026.
• Per Business Quant, the three latest REGN Total Non-Current Liabilities figures stand at $7.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $7.3 billion (Q3 2025).